Publication date: Sep 21, 2023
Genetically engineered immune cells expressing chimeric antigen receptors (CARs) have emerged as a new game changer in cancer immunotherapy. The utility of CAR T cell therapy against hematological malignancies has been validated in clinical practice. Other CAR immune cells are currently under investigation to improve the potency of CAR therapy in solid tumors. As a new class of therapeutic modalities, mRNA-based therapeutics hold enormous potential beyond COVID-19 mRNA vaccines. Arming immune cells with mRNA-encoded CARs represents a new frontier in cancer and beyond, enabling in vivo generation of CAR cells without causing transgene integration. In this review, we summarize recent advances in mRNA-based CAR immunotherapies and highlight their opportunities and challenges for the development of a new generation of living drugs.
| Concepts | Keywords |
|---|---|
| Biotechnol | chimeric antigen receptor |
| Cars | delivery system |
| Hematological | immune cell |
| Mrna | immunotherapy |
| Vaccines | mRNA |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | cancer |
| disease | IDO | cell |
| disease | MESH | hematological malignancies |
| disease | MESH | COVID-19 |